Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLC—Real World Efficacy

SIMPLE SUMMARY: The expected change in overall survival (OS) in patients with advanced non-small cell lung cancer (NSCLC) after the clinical implementation of immune checkpoint inhibitor therapy (ICI) has not been substantially investigated in large real-world cohorts outside randomized controlled t...

Descripción completa

Detalles Bibliográficos
Autores principales: Mouritzen, Mette T., Carus, Andreas, Ladekarl, Morten, Meldgaard, Peter, Nielsen, Anders W. M., Livbjerg, Anna, Larsen, Jacob W., Skuladottir, Halla, Kristiansen, Charlotte, Wedervang, Kim, Schytte, Tine, Hansen, Karin H., Østby, Anne-Cathrine, Frank, Malene S., Lauritsen, Jakob, Sørensen, Jens B., Langer, Seppo W., Persson, Gitte F., Andersen, Jon L., Frary, Johanna M. C., Drivsholm, Lars B., Vesteghem, Charles, Christensen, Heidi S., Bjørnhart, Birgitte, Pøhl, Mette
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507718/
https://www.ncbi.nlm.nih.gov/pubmed/34638329
http://dx.doi.org/10.3390/cancers13194846

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507718/
https://www.ncbi.nlm.nih.gov/pubmed/34638329
http://dx.doi.org/10.3390/cancers13194846

Ejemplares similares